Research ExplorerPublicationsKi67 measured after neoadjuvant chemotherapy for primary bre...

Ki67 measured after neoadjuvant chemotherapy for primary breast cancer

Standard

Ki67 measured after neoadjuvant chemotherapy for primary breast cancer. / von Minckwitz, Gunter; Schmitt, Wolfgang D; Loibl, Sibylle; Müller, Berit M; Blohmer, Jens U; Sinn, Bruno V; Eidtmann, Holger; Eiermann, Wolfgang; Gerber, Bernd; Tesch, Hans; Hilfrich, Jörn; Huober, Jens; Fehm, Tanja; Barinoff, Jana; Rüdiger, Thomas; Erbstoesser, Erhard; Fasching, Peter A; Karn, Thomas; Müller, Volkmar; Jackisch, Christian; Denkert, Carsten.

In: CLIN CANCER RES, Vol. 19, No. 16, 15.08.2013, p. 4521-31.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

von Minckwitz, G, Schmitt, WD, Loibl, S, Müller, BM, Blohmer, JU, Sinn, BV, Eidtmann, H, Eiermann, W, Gerber, B, Tesch, H, Hilfrich, J, Huober, J, Fehm, T, Barinoff, J, Rüdiger, T, Erbstoesser, E, Fasching, PA, Karn, T, Müller, V, Jackisch, C & Denkert, C 2013, 'Ki67 measured after neoadjuvant chemotherapy for primary breast cancer', CLIN CANCER RES, vol. 19, no. 16, pp. 4521-31. https://doi.org/10.1158/1078-0432.CCR-12-3628

APA

von Minckwitz, G., Schmitt, W. D., Loibl, S., Müller, B. M., Blohmer, J. U., Sinn, B. V., Eidtmann, H., Eiermann, W., Gerber, B., Tesch, H., Hilfrich, J., Huober, J., Fehm, T., Barinoff, J., Rüdiger, T., Erbstoesser, E., Fasching, P. A., Karn, T., Müller, V., ... Denkert, C. (2013). Ki67 measured after neoadjuvant chemotherapy for primary breast cancer. CLIN CANCER RES, 19(16), 4521-31. https://doi.org/10.1158/1078-0432.CCR-12-3628

Vancouver

von Minckwitz G, Schmitt WD, Loibl S, Müller BM, Blohmer JU, Sinn BV et al. Ki67 measured after neoadjuvant chemotherapy for primary breast cancer. CLIN CANCER RES. 2013 Aug 15;19(16):4521-31. https://doi.org/10.1158/1078-0432.CCR-12-3628

Bibtex

@article{8716d53ec579413aa0c0b27ed05a452f,
title = "Ki67 measured after neoadjuvant chemotherapy for primary breast cancer",
abstract = "PURPOSE: The value of Ki67 measured on residual disease after neoadjuvant chemotherapy is not sufficiently described.EXPERIMENTAL DESIGN: Participants of the GeparTrio study with primary breast cancer randomly received neoadjuvant response-guided [8 cycles TAC (docetaxel/doxorubicin/cyclophosphamide) in responding and TAC-NX (vinorelbine/capecitabine) in nonresponding patients] or conventional (6 cycles TAC) chemotherapy according to interim response assessment. Ki-67 levels were centrally measured immunohistochemically after neoadjuvant treatment if tumor tissue was available. Here, we analyze 1,151 patients having a pathologic complete response (pCR; n, 484), or residual disease with low (0-15%), intermediate (15.1-35%), or high (35.1-100%) posttreatment Ki67 levels in 488, 77, and 102 patients, respectively.RESULTS: Patients with high posttreatment Ki67 levels showed higher risk for disease relapse (P < 0.0001) and death (P < 0.0001) compared with patients with low or intermediate Ki67 levels. Patients with low Ki67 levels showed a comparable outcome to patients with a pCR (P = 0.211 for disease-free and P = 0.779 for overall survival). Posttreatment Ki67 levels provided more prognostic information than pretreatment Ki67 levels or changes of Ki67 from pre- to posttreatment. Information on pCR plus posttreatment Ki67 levels surmount the prognostic information of pCR alone in hormone-receptor-positive disease [hazard ratios (HR), 1.82-5.88] but not in hormone-receptor-negative disease (HR: 0.61-1.73). Patients with conventional and response-guided treatment did not show a different distribution of posttreatment Ki67 (P = 0.965).CONCLUSIONS: Posttreatment Ki67 levels provide prognostic information for patients with hormone-receptor-positive breast cancer and residual disease after neoadjuvant chemotherapy. Levels were not prognostic for outcome after response-guided chemotherapy. High posttreatment Ki67 indicates the need for innovative postneoadjuvant treatments.",
keywords = "Adult, Aged, Breast Neoplasms, Chemotherapy, Adjuvant, Female, Humans, Ki-67 Antigen, Middle Aged, Neoadjuvant Therapy, Neoplasm Grading, Neoplasm Staging, Prognosis, Treatment Outcome, Tumor Burden, Young Adult",
author = "{von Minckwitz}, Gunter and Schmitt, {Wolfgang D} and Sibylle Loibl and M{\"u}ller, {Berit M} and Blohmer, {Jens U} and Sinn, {Bruno V} and Holger Eidtmann and Wolfgang Eiermann and Bernd Gerber and Hans Tesch and J{\"o}rn Hilfrich and Jens Huober and Tanja Fehm and Jana Barinoff and Thomas R{\"u}diger and Erhard Erbstoesser and Fasching, {Peter A} and Thomas Karn and Volkmar M{\"u}ller and Christian Jackisch and Carsten Denkert",
note = "{\textcopyright}2013 AACR.",
year = "2013",
month = aug,
day = "15",
doi = "10.1158/1078-0432.CCR-12-3628",
language = "English",
volume = "19",
pages = "4521--31",
journal = "CLIN CANCER RES",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "16",

}

RIS

TY - JOUR

T1 - Ki67 measured after neoadjuvant chemotherapy for primary breast cancer

AU - von Minckwitz, Gunter

AU - Schmitt, Wolfgang D

AU - Loibl, Sibylle

AU - Müller, Berit M

AU - Blohmer, Jens U

AU - Sinn, Bruno V

AU - Eidtmann, Holger

AU - Eiermann, Wolfgang

AU - Gerber, Bernd

AU - Tesch, Hans

AU - Hilfrich, Jörn

AU - Huober, Jens

AU - Fehm, Tanja

AU - Barinoff, Jana

AU - Rüdiger, Thomas

AU - Erbstoesser, Erhard

AU - Fasching, Peter A

AU - Karn, Thomas

AU - Müller, Volkmar

AU - Jackisch, Christian

AU - Denkert, Carsten

N1 - ©2013 AACR.

PY - 2013/8/15

Y1 - 2013/8/15

N2 - PURPOSE: The value of Ki67 measured on residual disease after neoadjuvant chemotherapy is not sufficiently described.EXPERIMENTAL DESIGN: Participants of the GeparTrio study with primary breast cancer randomly received neoadjuvant response-guided [8 cycles TAC (docetaxel/doxorubicin/cyclophosphamide) in responding and TAC-NX (vinorelbine/capecitabine) in nonresponding patients] or conventional (6 cycles TAC) chemotherapy according to interim response assessment. Ki-67 levels were centrally measured immunohistochemically after neoadjuvant treatment if tumor tissue was available. Here, we analyze 1,151 patients having a pathologic complete response (pCR; n, 484), or residual disease with low (0-15%), intermediate (15.1-35%), or high (35.1-100%) posttreatment Ki67 levels in 488, 77, and 102 patients, respectively.RESULTS: Patients with high posttreatment Ki67 levels showed higher risk for disease relapse (P < 0.0001) and death (P < 0.0001) compared with patients with low or intermediate Ki67 levels. Patients with low Ki67 levels showed a comparable outcome to patients with a pCR (P = 0.211 for disease-free and P = 0.779 for overall survival). Posttreatment Ki67 levels provided more prognostic information than pretreatment Ki67 levels or changes of Ki67 from pre- to posttreatment. Information on pCR plus posttreatment Ki67 levels surmount the prognostic information of pCR alone in hormone-receptor-positive disease [hazard ratios (HR), 1.82-5.88] but not in hormone-receptor-negative disease (HR: 0.61-1.73). Patients with conventional and response-guided treatment did not show a different distribution of posttreatment Ki67 (P = 0.965).CONCLUSIONS: Posttreatment Ki67 levels provide prognostic information for patients with hormone-receptor-positive breast cancer and residual disease after neoadjuvant chemotherapy. Levels were not prognostic for outcome after response-guided chemotherapy. High posttreatment Ki67 indicates the need for innovative postneoadjuvant treatments.

AB - PURPOSE: The value of Ki67 measured on residual disease after neoadjuvant chemotherapy is not sufficiently described.EXPERIMENTAL DESIGN: Participants of the GeparTrio study with primary breast cancer randomly received neoadjuvant response-guided [8 cycles TAC (docetaxel/doxorubicin/cyclophosphamide) in responding and TAC-NX (vinorelbine/capecitabine) in nonresponding patients] or conventional (6 cycles TAC) chemotherapy according to interim response assessment. Ki-67 levels were centrally measured immunohistochemically after neoadjuvant treatment if tumor tissue was available. Here, we analyze 1,151 patients having a pathologic complete response (pCR; n, 484), or residual disease with low (0-15%), intermediate (15.1-35%), or high (35.1-100%) posttreatment Ki67 levels in 488, 77, and 102 patients, respectively.RESULTS: Patients with high posttreatment Ki67 levels showed higher risk for disease relapse (P < 0.0001) and death (P < 0.0001) compared with patients with low or intermediate Ki67 levels. Patients with low Ki67 levels showed a comparable outcome to patients with a pCR (P = 0.211 for disease-free and P = 0.779 for overall survival). Posttreatment Ki67 levels provided more prognostic information than pretreatment Ki67 levels or changes of Ki67 from pre- to posttreatment. Information on pCR plus posttreatment Ki67 levels surmount the prognostic information of pCR alone in hormone-receptor-positive disease [hazard ratios (HR), 1.82-5.88] but not in hormone-receptor-negative disease (HR: 0.61-1.73). Patients with conventional and response-guided treatment did not show a different distribution of posttreatment Ki67 (P = 0.965).CONCLUSIONS: Posttreatment Ki67 levels provide prognostic information for patients with hormone-receptor-positive breast cancer and residual disease after neoadjuvant chemotherapy. Levels were not prognostic for outcome after response-guided chemotherapy. High posttreatment Ki67 indicates the need for innovative postneoadjuvant treatments.

KW - Adult

KW - Aged

KW - Breast Neoplasms

KW - Chemotherapy, Adjuvant

KW - Female

KW - Humans

KW - Ki-67 Antigen

KW - Middle Aged

KW - Neoadjuvant Therapy

KW - Neoplasm Grading

KW - Neoplasm Staging

KW - Prognosis

KW - Treatment Outcome

KW - Tumor Burden

KW - Young Adult

U2 - 10.1158/1078-0432.CCR-12-3628

DO - 10.1158/1078-0432.CCR-12-3628

M3 - SCORING: Journal article

C2 - 23812670

VL - 19

SP - 4521

EP - 4531

JO - CLIN CANCER RES

JF - CLIN CANCER RES

SN - 1078-0432

IS - 16

ER -